Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
165 studies found for:    Open Studies | "Blood Platelet Disorders"
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Unknown  Thrombocytopathy in Gaucher Disease Patients
Conditions: Gaucher Disease;   Thrombocytopathy
Intervention:
2 Recruiting Effects of Exercise Training on Cardiovascular Health in Middle-aged Women
Conditions: Menopause;   Cardiac Function Impaired;   Cardiovascular Diseases;   Blood Platelet Disorders;   Metabolic Diseases
Interventions: Behavioral: Yoga/Pilates;   Behavioral: Spinning
3 Recruiting A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF
Conditions: Primary Myelofibrosis;   Thrombocythemia, Essential;   Thrombocytosis;   Myeloproliferative Disorders;   Bone Marrow Diseases;   Hematologic Diseases;   Blood Coagulation Disorders;   Blood Platelet Disorders;   Hemorrhagic Disorders
Interventions: Drug: LDE225;   Drug: INC424
4 Not yet recruiting Use of Proteomics for the Diagnosis of a Platelet-related Bleeding Disorder
Condition: Inherited Platelet Disorders
Intervention: Other: Blood collection for platelet protein samples
5 Recruiting Safety and Efficacy of Eltrombopag at Escalated Doses
Conditions: Immune Thrombocytopenia;   Platelet Disorder
Interventions: Drug: Eltrombopag;   Drug: Placebo
6 Recruiting Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
Conditions: Primary Myelofibrosis;   Post-polycythemia Vera Myelofibrosis;   Post-essential Thrombocythemia Myelofibrosis
Interventions: Drug: Pacritinib;   Drug: Best Available Therapy
7 Recruiting ICON1: Treatment Decisions and Outcomes in Pediatric Refractory ITP
Condition: Immune Thrombocytopenia
Intervention: Drug: Second Line ITP agents
8 Recruiting Surveillance of Safety and Efficacy of Wilate in Patients With Von Willebrand Disease
Condition: Von Willebrand Disease
Intervention: Other: Patients using wilate as standard of care
9 Unknown  Secondary Prophylaxis in Non-Hodgkin Lymphoma (NHL) and Chemotherapy-induced Thrombocytopenia
Condition: Non-Hodgkin Lymphoma
Intervention: Drug: Romiplostim
10 Recruiting Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing an Elective Procedure
Condition: Thrombocytopenia Associated With Liver Disease
Interventions: Drug: avatrombopag (lower baseline platelet count);   Drug: placebo (lower baseline platlet count);   Drug: avatrombopag (higher baseline platelet count);   Drug: placebo (higher baseline platelet count)
11 Recruiting A Trial of Eltrombopag or Intravenous Immune Globulin Before Surgery for Immune Thrombocytopenia Patients
Condition: Immune Thrombocytopenic Purpura
Interventions: Drug: Eltrombopag;   Drug: IVIG infusion
12 Not yet recruiting Octaplas Adult TTP Trial
Condition: Thrombotic Thrombocytopenic Purpura
Intervention: Biological: Octaplas
13 Recruiting Polymorphism and Auto-reactive B and T Cells Subsets in Adult's Immune Thrombocytopenia (ITP)
Condition: Immune Thrombocytopenia
Intervention: Other: blood sample
14 Recruiting The Alteration of Macrophage Function in the Spleen Tissues From Patients With Primary Immune Thrombocytopenia
Condition: Immune Thrombocytopenia
Intervention:
15 Recruiting Research Tissue Bank
Conditions: Myelofibrosis;   Idiopathic Myelofibrosis;   Essential Thrombocythemia;   Polycythemia Vera
Intervention:
16 Recruiting Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies
Conditions: Accelerated Phase Chronic Myelogenous Leukemia;   Acute Myeloid Leukemia/Transient Myeloproliferative Disorder;   Acute Undifferentiated Leukemia;   Angioimmunoblastic T-cell Lymphoma;   Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative;   Blastic Phase Chronic Myelogenous Leukemia;   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Myeloid Leukemia in Remission;   Childhood Burkitt Lymphoma;   Childhood Chronic Myelogenous Leukemia;   Childhood Diffuse Large Cell Lymphoma;   Childhood Grade III Lymphomatoid Granulomatosis;   Childhood Immunoblastic Large Cell Lymphoma;   Childhood Myelodysplastic Syndromes;   Childhood Nasal Type Extranodal NK/T-cell Lymphoma;   Chronic Eosinophilic Leukemia;   Chronic Myelomonocytic Leukemia;   Chronic Neutrophilic Leukemia;   Chronic Phase Chronic Myelogenous Leukemia;   Cutaneous B-cell Non-Hodgkin Lymphoma;   Essential Thrombocythemia;   Extramedullary Plasmacytoma;   Intraocular Lymphoma;   Isolated Plasmacytoma of Bone;   Juvenile Myelomonocytic Leukemia;   Long-term Effects Secondary to Cancer Therapy in Children;   Mast Cell Leukemia;   Meningeal Chronic Myelogenous Leukemia;   Monoclonal Gammopathy of Undetermined Significance;   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Polycythemia Vera;   Post-transplant Lymphoproliferative Disorder;   Primary Central Nervous System Hodgkin Lymphoma;   Primary Central Nervous System Non-Hodgkin Lymphoma;   Primary Myelofibrosis;   Primary Systemic Amyloidosis;   Progressive Hairy Cell Leukemia, Initial Treatment;   Prolymphocytic Leukemia;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndromes;   Stage 0 Chronic Lymphocytic Leukemia;   Stage I Childhood Anaplastic Large Cell Lymphoma;   Stage I Childhood Hodgkin Lymphoma;   Stage I Childhood Large Cell Lymphoma;   Stage I Childhood Lymphoblastic Lymphoma;   Stage I Childhood Small Noncleaved Cell Lymphoma;   Stage I Chronic Lymphocytic Leukemia;   Stage I Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage I Multiple Myeloma;   Stage I Mycosis Fungoides/Sezary Syndrome;   Stage II Childhood Anaplastic Large Cell Lymphoma;   Stage II Childhood Hodgkin Lymphoma;   Stage II Childhood Large Cell Lymphoma;   Stage II Childhood Lymphoblastic Lymphoma;   Stage II Childhood Small Noncleaved Cell Lymphoma;   Stage II Chronic Lymphocytic Leukemia;   Stage II Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage II Multiple Myeloma;   Stage II Mycosis Fungoides/Sezary Syndrome;   Stage III Childhood Anaplastic Large Cell Lymphoma;   Stage III Childhood Hodgkin Lymphoma;   Stage III Childhood Large Cell Lymphoma;   Stage III Childhood Lymphoblastic Lymphoma;   Stage III Childhood Small Noncleaved Cell Lymphoma;   Stage III Chronic Lymphocytic Leukemia;   Stage III Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage III Multiple Myeloma;   Stage III Mycosis Fungoides/Sezary Syndrome;   Stage IV Childhood Anaplastic Large Cell Lymphoma;   Stage IV Childhood Hodgkin Lymphoma;   Stage IV Childhood Large Cell Lymphoma;   Stage IV Childhood Lymphoblastic Lymphoma;   Stage IV Childhood Small Noncleaved Cell Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage IV Mycosis Fungoides/Sezary Syndrome;   T-cell Large Granular Lymphocyte Leukemia;   Unspecified Childhood Solid Tumor, Protocol Specific;   Untreated Childhood Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies;   Untreated Hairy Cell Leukemia;   Waldenström Macroglobulinemia
Interventions: Other: survey administration;   Procedure: assessment of therapy complications;   Procedure: long-term screening;   Procedure: study of high risk factors
17 Recruiting Myeloproliferative Neoplasms: an In-depth Case-control Study
Conditions: Polycythemia Vera;   Essential Thrombocythemia;   Primary Myelofibrosis
Interventions: Other: Methodological pens;   Other: Methodological compensation;   Other: Methodological trolley tokens
18 Recruiting Eltrombopag for Management of Thrombocytopenia
Condition: Leukemia
Intervention: Drug: Eltrombopag
19 Recruiting Extended Platelet Parameters as a Means to Differentiate Immune Thrombocytopenia From Hypo-proliferative Thrombocytopenias.
Conditions: Immune Thrombocytopenia;   Chemotherapy Induced Thrombocytopenia;   Myelodysplasia Related Thrombocytopenia;   Aplastic Anaemia Related Thrombocytopenia
Intervention: Other: Full blood count with extended platelet parameters
20 Unknown  The Role of Traditional Chinese Medicine in the Treatment of Chronic Childhood Immune Thrombocytopenia (ITP)
Condition: Childhood Chronic Immune Thrombocytopenia
Intervention: Drug: Bu Zhong Yi Qi Tang, Zhi Xue Tang, Chuan xin lian kang yan pian mod, Tian Wang Bu xin Dan

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years